In Development for the Treatment of Moderate-to-Severe Ulcerative Colitis
PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing.
Meets all the criteria of our Precision Delivery platform
Abdominal Adhesions are a Significant Medical Burden
Post Operative Bowel Function is a Big Bottleneck
- Delayed bowel movement causes prolonged hospital stays and increased costs